treatment with CAZ-AVI
Phase 3Small molecule
treatment with CAZ-AVI is one of 9 small molecule programs targeting Carbapenem-Resistant Enterobacteriaceae Infection. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Critically Ill Patients
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Depo-Testosterone
AAzurity Pharmaceuticals
Approved
treatment with CAZ-AVI
SSoutheast University, China
Phase 3
Prostigmin
Merck & Co.Preclinical
Albumin
LLaboratoire français de Fractionnement et de Biotechnologies
Preclinical
Magnesium
SSpherium Biomed
Preclinical
Fufang E'jiao Jiang
XXiyuan Hospital of China Academy of Chinese Medical Sciences
Preclinical
Degludec Insulin
Sunshine Lake Pharma Co., Ltd.Preclinical
Beta-Lactams
NNational Taiwan University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Carbapenem-Resistant Enterobacteriaceae Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for treatment with CAZ-AVI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSoutheast University, China